Learn more →
Back to Expert Scholars
thoracic-oncology / thoracic-oncologyLiquid Biopsy in Lung Cancer

Geoffrey R. Oxnard

杰弗里·奥克斯纳德

MD

🏢Foundation Medicine / Harvard Medical School(Foundation Medicine / 哈佛医学院)🌐USA

Chief Medical Officer, Foundation Medicine; Associate Professor of MedicineFoundation Medicine首席医疗官;副教授

58
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Dr. Geoffrey Oxnard is a global leader in liquid biopsy application for lung cancer, pioneering plasma ctDNA testing for EGFR resistance detection. His work bridges genomic technology and clinical decision-making for NSCLC patients worldwide.

Share:

🧪Research Fields 研究领域

Thoracic Oncology胸部肿瘤学
Liquid Biopsy液态活检
ctDNA循环肿瘤DNA
EGFR-Mutant NSCLCEGFR突变非小细胞肺癌

🎓Key Contributions 主要贡献

Plasma ctDNA for EGFR Resistance Detection

Demonstrated that plasma genotyping could detect T790M and other resistance mutations non-invasively, enabling treatment selection without repeat tissue biopsy in EGFR-mutant NSCLC.

Cell-Free DNA Cancer Screening

Led clinical development of multi-cancer early detection through cfDNA, including key validation studies for Galleri test, advancing population-level cancer screening science.

Osimertinib Resistance Landscape

Characterized the diverse on-target and off-target mechanisms of acquired resistance to osimertinib through large-scale plasma sequencing, guiding next-generation combination strategies.

Representative Works 代表性著作

[1]

Plasma Genotyping for Therapeutic Targets in EGFR-Mutant Lung Cancer

Journal of Thoracic Oncology (2016)

Validated plasma EGFR testing as a clinically actionable tool for resistance monitoring, transforming the practice of NSCLC disease surveillance.

[2]

Detection of Cell-Free DNA Alterations for Multi-Cancer Early Detection

Annals of Oncology (2020)

Landmark validation study showing cfDNA methylation patterns can signal cancer presence across multiple tumor types with high specificity.

[3]

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291

Nature Medicine (2015)

First comprehensive characterization of osimertinib resistance mechanisms, identifying C797S and bypass pathways that remain clinically relevant.

🏆Awards & Recognition 奖项与荣誉

🏆ASCO Young Investigator Award
🏆Lung Cancer Research Foundation Grant Award
🏆American Lung Association Lung Cancer Discovery Award
🏆IASLC Presidential Select Abstract Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 杰弗里·奥克斯纳德 的研究动态

Follow Geoffrey R. Oxnard's research updates

留下邮箱,当我们发布与 Geoffrey R. Oxnard(Foundation Medicine / Harvard Medical School)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment